SubHero Banner

Trulicity® (dulaglutide) – New indication

February 21, 2020 - Eli Lilly announced the FDA approval of Trulicty (dulaglutide), to reduce the risk of major adverse cardiovascular events (MACE) (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus (T2DM) who have established cardiovascular (CV) disease or multiple CV risk factors.

Download PDF